• Home
  • Search Results

Search Results

432 studies match your search
By physician referral or invitation only

TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)

This is an exploratory study in cancer biomarker research, hoping to identify cell-signaling using DNA, in patients with SCLC.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
  • Lungs and Breathing
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

GEMINI-NSCLC: TEMPUS NSCLC SURVEILLANCE STUDY

The purpose of this study is to evaluate a new test being developed by Tempus for patients with Non-Small Cell Lung Cancer (NSCLC). The goal of this new test is to predict the likelihood of a patient's cancer coming back after treatment, and to further explore changes in patient's tumors throughout treatment to see how they respond.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
  • Lungs and Breathing
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

EASINESS Prospective molecular analysis In metastatic breast cancer patients treated with antibody drug conjugates

The purpose of this study is to determine if it is possible to identify biomarkers that tell us what type of response a person with metastatic breast cancer (MBC) will have to "antibody-drug conjugates" (ADCs).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

A Multi-Institution Study of Universal Donor NK Cell Infusions in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue Sarcomas: The TiNKS Trial

The purpose of this study is to determine the safety of the addition of universal donor, expanded NK cells to gemcitabine/docetaxel for treatment of relapsed and refractory sarcomas.

Age & Gender
  • 1 years ~ 19 years
  • Male, Female, Gender Inclusive
Study Interest
  • Bones, Joints, Muscles
  • Cancer (Pediatric Cancers, Sarcoma (bone and soft tissue))
  • Child and Teen Health
Visit Location
100% Remote (online, phone, text)

APEC1621: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Protocol

The purpose of this study is to assess the efficacy as well as safety and tolerability of a new drug called padsevonil that will be given in one of 3 different doses in addition to your current epilepsy treatment that may consist of 1-3 antiepileptic drugs. The study also aims to see how safe padsevonil is compared to placebo and how well your body can tolerate it.

Age & Gender
  • 1 years ~ 21 years
  • Male, Female
Study Interest
  • Cancer (Pediatric Cancers)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Health Education Approach for Lung Screening (HEALS)

To initiate and evaluate a multilevel navigation intervention to promote lung cancer screening among Black/African Americans

Age & Gender
  • 50 years ~ 80 years
  • Male, Female
Study Interest
  • Cancer (Lung)
  • Lungs and Breathing
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades despite numerous attempts to augment standard therapies. Multi-targeted receptor tyrosine kinase inhibitors (MTKIs), such as cabozantinib, can target signaling pathways that are known to be altered in osteosarcoma. Several MTKIs including cabozantinib have recently shown clinical evidence of activity in prospective studies for both pediatric and adult patients with advanced osteosarcoma. Furthermore, feasibility of administering MTKIs in combination with cytotoxic chemotherapy has previously been shown in patients with AML, hepatocellular carcinoma, and soft tissue sarcomas. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades

Age & Gender
  • 0 days ~ 40 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pediatric Cancers, Sarcoma (bone and soft tissue))
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

ACCL1931 - Levocarnitine as Prophylaxis for Hepatotoxicity in AYA (15-39.9) with de novo ALL/Lly/MPAL

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

Age & Gender
  • 15 years ~ 39.9 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pediatric Cancers, Leukemia)
  • Kidneys and Liver
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Nasal Swab to Evaluate Lung Cancer Risk

The DNA that we can test from a nasal swab, can help us determine a patient's lung cancer risk. For patients with new lung nodules found on CT scans, we are offering this nasal swab test and collecting data on how physicians use test results to help assess risk and determine treatment strategies.

Age & Gender
  • 29 years ~ 85 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
  • Lungs and Breathing
Visit Location
100% Remote (online, phone, text)
Not currently enrolling

Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder)
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research